Antibody-drug conjugate · Immune activation, directed at claudin 18.2 (CLDN18) · developed by Bolt Biotherapeutics
BDC-4182 is an immune stimulating antibody conjugate made of an anti-claudin 18.2 monoclonal antibody linked to a TLR 7/8 dual agonist. The antibody directs the conjugate to claudin 18.2 on tumor cells, where the TLR 7/8 agonist payload stimulates innate immune activity. It is being studied in metastatic gastric and gastroesophageal adenocarcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06921837 | Phase 1/2 | Gastric Cancer Adenocarcinoma Metastatic | Recruiting | BOLT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Gastric Cancer Adenocarcinoma MetastaticGastroesophageal Adenocarcinoma
Updated Nov 8, 2026. Something wrong or missing? Report it on the BOLT page.
See BOLT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BOLT catalysts and pipeline →